Katana VentraIP

Factor IX

Factor IX (EC 3.4.21.22), also known as Christmas factor, is one of the serine proteases involved in coagulation; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B.

It was discovered in 1952 after a young boy named Stephen Christmas was found to be lacking this exact factor, leading to haemophilia.[5] Coagulation factor IX is on the World Health Organization's List of Essential Medicines.[6]

Clinical data

Benefix

  • None

  • AU: S4 (Prescription only)

Rixubis

  • None

Idelvion

  • None

Alprolix

  • None

  • AU: S4 (Prescription only)
  • EU: Rx-only[20]

Refixia

  • None

  • AU: S4 (Prescription only)

nonacog alfa (brand name Benefix)

[23]

nonacog gamma (brand name Rixubis)

[18]

albutrepenonacog alfa (brand name Idelvion)

[24]

eftrenonacog alfa (brand name Alprolix)

[25]

nonacog beta pegol (brand name Refixia)

[26]

coagulation factor IX [recombinant] (Benefix)

[27]

coagulation factor IX [recombinant] (Idelvion)

[28]

coagulation factor IX (recombinant), Fc fusion protein (Alprolix)

[29]

coagulation factor IX [recombinant] (Ixinity)[31]

[30]

coagulation factor IX [recombinant] (Rebinyn)

[32]

coagulation factor IX [recombinant] (Rixubis)

[33]

coagulation factor IX (human) (Alphanine SD)

[34]

Deficiency of factor IX causes Christmas disease (hemophilia B).[5] Over 3000 variants of factor IX have been described, affecting 73% of the 461 residues;[21] some cause no symptoms, but many lead to a significant bleeding disorder. The original Christmas disease mutation was identified by sequencing of Christmas' DNA, revealing a mutation which changed a cysteine to a serine.[22] Recombinant factor IX is used to treat Christmas disease. Formulations include:


Some rare mutations of factor IX result in elevated clotting activity, and can result in clotting diseases, such as deep vein thrombosis. This gain of function mutation renders the protein hyperfunctional and is associated with familial early-onset thrombophilia.[35]


Factor IX deficiency is treated by injection of purified factor IX produced through cloning in various animal or animal cell vectors. Tranexamic acid may be of value in patients undergoing surgery who have inherited factor IX deficiency in order to reduce the perioperative risk of bleeding.[36]


A list of all the mutations in Factor IX is compiled and maintained by EAHAD.[37]


Coagulation factor IX is on the World Health Organization's List of Essential Medicines.[6]

Overview of all the structural information available in the for UniProt: P00740 (Coagulation factor IX) at the PDBe-KB.

PDB

GeneReviews/NCBI/NIH/UW entry on Hemophilia B

The online database for peptidases and their inhibitors: S01.214 Archived 2005-05-05 at the Wayback Machine

MEROPS